3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Phase 1
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
CNS
1
Conditions
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Neoplasms, Plasma Cell
1
Myelodysplastic Syndromes
1
Leukemia, Myeloid, Acute
1
Hodgkin Disease
1
Gliosarcoma
1
Glioblastoma
1
Brain Neoplasms
1
Interventions
Temozolomide
107
Radiotherapy
60
Radiation
28
Bevacizumab
19
Magnetic Resonance Spectroscopy
16
Nivolumab
15
Surgical Procedures, Operative
12
Irinotecan
11
Cyclophosphamide
10
Specimen Handling
9
Chemotherapy, Adjuvant
9
Radiotherapy, Intensity-Modulated
8
Radiosurgery
8
O(6)-benzylguanine
8
Carmustine
8
poly ICLC
7
pembrolizumab
7
motexafin gadolinium
7
fludarabine
7
Leukapheresis
7
Flucytosine
7
sargramostim
6
Radiotherapy, Conformal
6
Erlotinib Hydrochloride
6
Lomustine
5
Ipilimumab
5
Imiquimod
5
Imatinib Mesylate
5
Hydroxyurea
5
Granulocyte-Macrophage Colony-Stimulating Factor
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1
×
Glioblastoma
×
Basiliximab
×
Clear all
NCT00626483
2021-03-09
REGULATe
Duke University
Phase 1
Completed
34 enrolled